Adult changes in thought study: Dementia is an individually varying convergent syndrome with prevalent clinically silent diseases that may be modified by some commonly used therapeutics

Current Alzheimer Research

Volumn 9, Issue 6, 2012, Pages 718-723

  Montine, Thomas J ^a   Sonnen, Joshua A ^a   Montine, Kathleen S ^a   Crane, Paul K ^a   Larson, Eric B ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Brain aging; Cognitive impairment; Neuropathology; Population based

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTIOXIDANT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ALZHEIMER DISEASE; ARTICLE; CEREBROVASCULAR DISEASE; CIGARETTE SMOKING; DEMENTIA; DIABETES MELLITUS; HUMAN; LEWY BODY; MICROVASCULAR BRAIN INJURY; NONHUMAN; PRIORITY JOURNAL;

EID: 84863556310     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/156720512801322555     Document Type: Article

References (48)

1. Kukull WA, Higdon R, Bowen JD, McCormick WC, Teri L, Schellenberg GD, et al. Dementia and Alzheimer Disease Incidence. Arch Neurol 59: 1737-1746 (2002).
2. Sonnen JA, Larson EB, Haneuse S, Woltjer R, Li G, Crane PK, et al. Neuropathology in the Adult Changes in Thought Study: A Review. J Alzheimers Dis 18(3): 703-11 (2009).
3. White L. Brain Lesions at Autopsy in Older Japanese-American Men as Related to Cognitive Impairment and Dementia in the Final Years of Life: A Summary Report from the Honolulu-Asia Aging Study. J Alzheimers Dis 18(3): 713-25 (2009).
4. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 277: 813-817 (1997).
5. Schneider JA, Aggarwal NT, Barnes L, Boyle P, Bennett DA. The neuropathology of older persons with and without dementia from community versus clinic cohorts. J Alzheimers Dis 18: 691-701 (2009).
6. Haneuse S, Schildcrout J, Crane P, Sonnen J, Breitner J, Larson E. Adjustment for Selection Bias in Observational Studies with Application to the Analysis of Autopsy Data. Neuroepidemiology 32: 229-239 (2009).
7. Teng EL, Hasegawa K, Homma A, Imai Y, Larson E, Graves A, et al. The Cognitive Abilities Screening Instrument (CASI): a practical test for cross-cultural epidemiological studies of dementia. Int Psychogeriatr 6: 45-58 (1994).
8. Larson EB. Population-based neuropathology: the best of times. J Alzheimers Dis 18: 643-644 (2009).
9. Brayne C, Richardson K, Matthews FE, Fleming J, Hunter S, Xuereb JH, et al. Neuropathological correlates of dementia in over-80-yearold brain donors from the population-based Cambridge city over-75s cohort (CC75C) study. J Alzheimers Dis 18: 645-658 (2009).
10. Cohort profile: Epidemiological Clinicopathological studies in Europe (EClipSE). J Alzheimers Dis 18: 659-663 (2009).
11. O'Brien RJ, Resnick SM, Zonderman AB, Ferrucci L, Crain BJ, Pletnikova O, et al. Neuropathologic studies of the Baltimore Longitudinal Study of Aging (BLSA). J Alzheimers Dis 18: 665-675 (2009).
12. Oinas M, Polvikoski T, Sulkava R, Myllykangas L, Juva K, Notkola IL, et al. Neuropathologic findings of dementia with lewy bodies (DLB) in a population-based Vantaa 85+ study. J Alzheimers Dis 18: 677-689 (2009).
13. Sonnen JA, Larson EB, Crane PK, Haneuse S, Li G, Schellenberg GD, et al. Pathological correlates of dementia in a longitudinal, population- based sample of aging. Ann Neurol 62: 406-413 (2007).
14. White L, Petrovitch H, Hardman J, Nelson J, Davis DG, Ross GW, et al. Cerebrovascular pathology and dementia in autopsied Honolulu- Asia Aging Study participants. Ann NY Acad Sci 977: 9-23 (2002).
15. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 82: 239-259 (1991).
16. Leverenz JB, McKeith IG. Dementia with Lewy bodies. Med Clin North Am 86: 519-535 (2002).
17. Mirra SS. The CERAD neuropathology protocol and consensus recommendations for the postmortem diagnosis of Alzheimer's disease: a commentary. Neurobiol Aging 18: S91-94 (1997).
18. Iacono D, Markesbery WR, Gross M, Pletnikova O, Rudow G, Zandi P, et al. The Nun study: clinically silent AD, neuronal hypertrophy, and linguistic skills in early life. Neurology 73: 665-673 (2009).
19. Price JL, McKeel DW, Jr., Buckles VD, Roe CM, Xiong C, Grundman M, et al. Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging 30: 1026-1036 (2009).
20. Yaffe K, Barrett-Connor E, Lin F, Grady D. Serum lipoprotein levels, statin use, and cognitive function in older women. Arch Neurol 59: 378-384 (2002).
21. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet 356: 1627-1631 (2000).
22. Rockwood K, Kirkland S, Hogan DB, MacKnight C, Merry H, Verreault R, et al. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol 59: 223-227 (2002).
23. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3- hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 57: 1439-1443 (2000).
24. Zandi PP, Sparks DL, Khachaturian AS, Tschanz J, Norton M, Steinberg M, et al. Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Arch Gen Psychiatry 62: 217-224 (2005).
25. Rea TD, Breitner JC, Psaty BM, Fitzpatrick AL, Lopez OL, Newman AB, et al. Statin use and the risk of incident dementia: the Cardiovascular Health Study. Arch Neurol 62: 1047-1051 (2005).
26. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360: 7-22 (2002).
27. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360: 1623-1630 (2002).
28. Li G, Higdon R, Kukull WA, Peskind E, Van Valen Moore K, Tsuang D, et al. Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study. Neurology 63: 1624- 1628 (2004).
29. Li G, Kukull WA, Peskind E, et al. Differential effect of statins on risk of AD by age, sex and APOE genotype: Findings from a community- based prospective cohort study. Alzheimer Dis Assoc Disord 20: S103-104 (2006).
30. Li G, Larson EB, Sonnen JA, Shofer JB, Petrie EC, Schantz A, et al. Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. Neurology 69: 878-885 (2007).
31. Knopman DS, Parisi JE, Salviati A, Floriach-Robert M, Boeve BF, Ivnik RJ, et al. Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol 62: 1087-1095 (2003).
32. Sonnen JA, Breitner JC, Lovell MA, Markesbery WR, Quinn JF, Montine TJ. Free radical-mediated damage to brain in Alzheimer's disease and its transgenic mouse models. Free Radic Biol Med 45: 219-230 (2008).
33. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, et al. A controlled trial of selegiline, alpha-tocopherol, or both as a treatment for Alzheimer's disease. New Engl J Med 336: 1216-1222 (1997).
34. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 352: 2379-2388 (2005).
35. Kang JH, Cook N, Manson J, Buring JE, Grodstein F. A randomized trial of vitamin E supplementation and cognitive function in women. Arch Intern Med 166: 2462-2468 (2006).
36. Gray SL, Anderson ML, Crane PK, Breitner JC, McCormick W, Bowen JD, et al. Antioxidant vitamin supplement use and risk of dementia or Alzheimer's disease in older adults. J Am Geriatr Soc 56: 291-295 (2008).
37. Sonnen JA, Larson EB, Gray SL, Wilson A, Kohama SG, Crane PK, et al. Free radical damage to cerebral cortex in Alzheimer's disease, microvascular brain injury, and smoking. Ann Neurol 65: 226-229 (2009).
38. VanRollins M, Woltjer RL, Yin H, Morrow JD, Montine TJ. F2- dihomo-isoprostanes arise from free radical attack on adrenic acid. J Lipid Res 49: 995-1005 (2008).
39. Sonnen JA, Larson EB, Brickell K, Crane PK, Woltjer R, Montine TJ, et al. Different Patterns of Cerebral Injury in Dementia With or Without Diabetes. Arch Neurol 66(3): 315-22 (2009).
40. Kalaria RN. Neurodegenerative disease: Diabetes, microvascular pathology and Alzheimer disease. Nat Rev Neurol 5: 305-306 (2009).
41. Berg L, McKeel DW, Jr., Miller JP, Storandt M, Rubin EH, Morris JC, et al. Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol 55: 326-335 (1998).
42. Lim A, Tsuang D, Kukull W, Nochlin D, Leverenz J, McCormick W, et al. Clinico-neuropathological correlation of Alzheimer's disease in a community-based case series. J Am Geriatr Soc 47: 564- 569 (1999).
43. Thacker EL, O'Reilly EJ, Weisskopf MG, Chen H, Schwarzschild MA, McCullough ML, et al. Temporal relationship between cigarette smoking and risk of Parkinson disease. Neurology 68: 764- 768 (2007).
44. Ritz B, Ascherio A, Checkoway H, Marder KS, Nelson LM, Rocca WA, et al. Pooled analysis of tobacco use and risk of Parkinson disease. Arch Neurol 64: 990-997 (2007).
45. Tan LC, Koh WP, Yuan JM, Wang R, Au WL, Tan JH, et al. Differential effects of black versus green tea on risk of Parkinson's disease in the Singapore Chinese Health Study. Am J Epidemiol 167: 553-560 (2008).
46. Quik M, O'Neill M, Perez XA. Nicotine neuroprotection against nigrostriatal damage: importance of the animal model. Trends Pharmacol Sci 28: 229-235 (2007).
47. Hernan MA, Alonso A, Logroscino G. Cigarette smoking and dementia: potential selection bias in the elderly. Epidemiology 19: 448-450 (2008).
48. Tsuang D, Larson EB, Li G, Shofer JB, Montine KS, Thompson ML, et al. Association Between Lifetime Cigarette Smoking and Lewy Body Accumulation. Brain Pathol 20(2): 412-8 (2009).